RECHERCHES SCIENTIFIQUES

MUTATION DU RECEPTEUR DU FACTEUR DE CROISSANCE EPIDERMIQUE (EGFR) DANS LE CANCER BRONCHIQUE METASTATIQUE

Référence903
Année2015
TypeThèse
Lien document
AuteurLyagoubi A
DisciplineOncologie Médicale
EncadrantMellas N

Introduction:Detection of epidermal growth factor receptor (EGFR) mutations in metastatic lung cancer predicts response to tyrosine kinase inhibitors. The profile of EGFR mutations is ethnicity-dependent, with a higher proportion in Asian populations. In Morocco a single retrospective study has been conducted.
Methods:We conducted a retrospective study that included 10 patients treated for metastatic lung cancer at the medical oncology department of CHU Hassan II of Fez, these patients underwent a screening for EGFR mutations. A descriptive study of this sample was performed. The obtained results were compared with similar studies.
Results:Ten patients were included in our study, with a sex ratio of 2/3, the mean age was 56.6 +/- 10.21 years [41-81], 60% of our sample reported a history of
smoking, all were men.All the cases studied had a grade IV adenocarcinoma.the frequency of the mutation was 30%, found exclusively in females and in non-smokers, 33.3% of the mutations were located in exon 21 (L858R mutation), 66.6% of the mutations were located in exon 19.Nine (90%) patients in our sample received special treatment, including one case that received tyrosine kinase inhibitors for first-line treatment, Response to treatment was similar in both groups.
No statistically significant difference was found regarding survival in both group

ConclusionThe EGFR mutation seems to be more common among women and among non-smokers, mutations located in exon 19 are more common than mutationslocated in exon 21.The Moroccan population has a rate of EGFR mutations that lies between that of Asians and that of Caucasians